Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitorsHitisha Patel(Radius Health (United States)), Teeru Bihani(AstraZeneca (United States))Breast Cancer ResearchDecember 1, 201910.1186/s13058-019-1230-0Cited by 77SaveCiteExport RISWatch citationsRelated PapersResistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers|Oncotarget|2014|57